 "Biocon hits 52-week high")
Biocon has moved higher by 6% to Rs 510, also its 52-week high on the BSE, after the company announced the introduction of an advanced novel therapy CIMIVIR-L for the treatment of Hepatitis C in India.
“CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is equivalent of the innovator product commercialized by Gilead Sciences in the US,” Biocon said in a statement.
The Drugs Controller General of India (DCGI) recently approved the sale of Sofosbuvir- Ledipasvir combination, which is being manufactured in India under a license from Gilead, it added.
CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV).
At 09:49 a.m. the stock was up 5% at Rs 508 on the BSE as compared to a marginal 0.05% decline in S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 959,130 shares changed hands on the counter on the NSE and BSE so far.
“CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is equivalent of the innovator product commercialized by Gilead Sciences in the US,” Biocon said in a statement.
The Drugs Controller General of India (DCGI) recently approved the sale of Sofosbuvir- Ledipasvir combination, which is being manufactured in India under a license from Gilead, it added.
CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV).
At 09:49 a.m. the stock was up 5% at Rs 508 on the BSE as compared to a marginal 0.05% decline in S&P BSE Sensex. The trading volumes on the counter more than doubled with a combined 959,130 shares changed hands on the counter on the NSE and BSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%